---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-025724"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:13:55.216467+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva completes acquisition of Entasis Therapeutics for $2.20/share, total ~$42.4M

## Summary
- Acquisition closed on July 11, 2022; Entasis becomes wholly-owned subsidiary of Innoviva.
- Total consideration of approximately $42.4M paid for all outstanding shares tendered at $2.20 per share.
- Entasis' pipeline includes SUL-DUR for Gram-negative bacteria; NDA submission planned for Q3 2022.
- Entasis common stock to be delisted from Nasdaq Global Market following acquisition.
- Innoviva funded the purchase from its own resources; deal creates new growth channel and diversifies revenue.

## SEC filing metadata
- accession: 0001140361-22-025724
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000114036122025724/0001140361-22-025724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000114036122025724/ny20004305x11_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-025724
- JSON: https://secwatch.observer/filing/0001140361-22-025724.json
- Plain text: https://secwatch.observer/filing/0001140361-22-025724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.